Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.

doi:10.1158/1078-0432.CCR-07-5165

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2008

Lurje Georg, Nagashima Fumio, Zhang Wu, Yang Dongyun, Chang Heung M, Gordon Michael A, El-Khoueiry Anthony, Husain Hatim, Wilson Peter M, Ladner Robert D, Mauro David J, Langer Christiane, Rowinsky Eric K, Lenz Heinz-Josef

Abstract excerpt

PURPOSE: Recently, an objective response rate of 12% was reported in a phase II study of cetuximab in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (IMC-0144). In this large molecular correlates study, we tested whether K-ras mutation status and polymorphisms in genes involved in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Clinical Trials, Phase II as Topic

Share to Cyclooxygenase 2

Share to Disease-Free Survival

Share to Epidermal Growth Factor

Share to Kaplan-Meier Estimate

Share to Multicenter Studies as Topic

Source

Open in PubMed

Identifiers

PMID: 19047118
DOI: 10.1158/1078-0432.CCR-07-5165

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.PMID 19047118Read ↗

Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with CetuximabSemantic proximity Read ↗

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.Semantic proximity Read ↗

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.Semantic proximity Read ↗

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.Semantic proximity Read ↗

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.Semantic proximity Read ↗

Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.Semantic proximity Read ↗

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.Semantic proximity Read ↗

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).Semantic proximity Read ↗

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.Semantic proximity Read ↗

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.Semantic proximity Read ↗

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient OutcomeSemantic proximity Read ↗

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.